UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2025
Commission File Number: 001-31368
SANOFI
(Translation of
registrant’s name into English)
46, avenue de la Grande Armée, 75017 Paris, FRANCE
(Address of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
1
In September 2025, Sanofi published the press releases attached hereto as Exhibits 99.1 and 99.2 which are
incorporated herein by reference.
Exhibit Index
|
|
|
| Exhibit No. |
|
Description |
|
|
| Exhibit 99.1 |
|
Press Release dated September
23, 2025: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 |
|
|
| Exhibit 99.2 |
|
Press Release dated September 24, 2025: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
| Dated: September 26, 2025 |
|
|
|
SANOFI |
|
|
|
|
|
|
|
|
By |
|
/s/ Alexandra Roger |
|
|
|
|
|
|
Name: Alexandra Roger |
|
|
|
|
|
|
Title: Head of Legal Corporate & Finance |
3
